Staszewski S - Search Results

1

A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.

Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P. Staszewski S, et al. HIV Med. 2000 Jul;1(3):162-3. doi: 10.1046/j.1468-1293.2000.00020.x. HIV Med. 2000. PMID: 11737345 Free article. No abstract available.

2

Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.

Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Staszewski S, et al. Antivir Ther. 1998;3 Suppl 4:55-6. Antivir Ther. 1998. PMID: 10723511 Clinical Trial.

3

Virological response to protease inhibitor therapy in an HIV clinic cohort.

Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A. Staszewski S, et al. AIDS. 1999 Feb 25;13(3):367-73. doi: 10.1097/00002030-199902250-00009. AIDS. 1999. PMID: 10199227

4

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A. Staszewski S, et al. AIDS. 1999 May 28;13(8):951-6. doi: 10.1097/00002030-199905280-00011. AIDS. 1999. PMID: 10371176

5

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC, Phillips AN. Miller V, et al. Among authors: staszewski s. J Infect Dis. 1999 Aug;180(2):530-3. doi: 10.1086/314890. J Infect Dis. 1999. PMID: 10395876

6

HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.

Miller V, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips A, Staszewski S. Miller V, et al. Among authors: staszewski s. Antivir Ther. 2000 Mar;5(1):49-55. doi: 10.1177/135965350000500113. Antivir Ther. 2000. PMID: 10846593

7

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S. Miller V, et al. Among authors: staszewski s. AIDS. 2000 Sep 29;14(14):2129-36. doi: 10.1097/00002030-200009290-00009. AIDS. 2000. PMID: 11061654 Clinical Trial.

8

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.

Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. Miller V, et al. Among authors: staszewski s. AIDS. 2000 Dec 22;14(18):2857-67. doi: 10.1097/00002030-200012220-00007. AIDS. 2000. PMID: 11153667

9

Mega-HAART: preliminary results and correlation with baseline resistance.

Rottmann C, Miller V, Staszewski S. Rottmann C, et al. Among authors: staszewski s. Antivir Ther. 1999;4 Suppl 3:93-4. Antivir Ther. 1999. PMID: 16021879

10

Dose reduction effective in alleviating symptoms of saquinavir toxicity.

Stephan C, Carlebach A, Rottmann C, Haberl A, Dauer B, von Hentig N, Kurowski M, Staszewski S. Stephan C, et al. Among authors: staszewski s. Int J STD AIDS. 2007 Feb;18(2):81-4. doi: 10.1258/095646207779949763. Int J STD AIDS. 2007. PMID: 17331276

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

251 results

Search Page

Filters